Jones Day’s Life Sciences Practice offers a distinctive combination of legal and technical skills to provide highly focused services to clients in the pharmaceutical, biotechnology, and medical device industries.

Our life sciences clients include multinational pharmaceutical companies, fully integrated biopharmaceutical companies, diagnostic and medical device companies, consumer products companies, nutraceutical companies, research institutions, and universities, as well as venture and private equity funds and investment banking institutions active in the life sciences arena.

Many of the lawyers in the practice have doctorates or master's degrees in relevant disciplines, including molecular biology, virology, immunology, genetics, neurobiology, structural biology, bioinformatics, physics, organic chemistry, medicinal chemistry, and biomedical engineering.

We work in teams to provide the full range of legal services required by life sciences clients in the relevant technology, including:

• Patent and trademark portfolio strategy, creation, and management.
• Intellectual property litigation, including patent interferences and oppositions.
• Intellectual property opinions, including validity, infringement, and peer review opinions.
• Due diligence for financings and mergers & acquisitions.
• Technology-driven agreements, including in-depth knowledge of cross-border licensing, collaborations, R&D partnerships, and consulting.
• Antitrust and competition law.
• Tax.

Jones Day has extensive experience with counseling and litigation related to the Hatch-Waxman Act, including the regulatory and antitrust issues intertwined with patent strategy and enforcement.

Our approach has assisted clients in achieving outstanding results, including the following:

• Represented Celgene in its patent strategy, licensing, and enforcement for its patents relating to THALOMID® and analogues.
• Represented MedImmune, Inc., and MedImmune Vaccines in connection with prosecution and enforcement of its patent portfolio relating to Ethyol®, Synagis®, Numax™, and genetically engineered influenza vaccines.
• Represented Hoffmann-La Roche Inc. in connection with multiple interferences involving interferons.
• Represented Genentech, Inc., in connection with patent infringement actions relating to Factor VIII for hemophiliacs.
• Represented Trimeris Pharmaceuticals, Inc., in connection with prosecution and defense of its patent portfolio relating to its anti-HIV drug, FUZEON®.

Contact(s)

Laura A. Coruzzi Ph.D.
New York
Tel: 1.212.326.3939
E-mail

Anthony M. Insogna
San Diego
Tel: 1.858.314.1200
E-mail

Peter Homberg
Munich
Tel: 49.89.20.60.42.200
E-mail